N. Cichanowitz

Statistics

Publications

Citations

803

H-Index

Active since

2003

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Oregon Medical Research Center

Probity Medical Research

Queen's University

Dermatologikum Hamburg

N. Cichanowitz is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, pharmacology, and clinical pharmacology.

Publications per year

2003–2019

Publications

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Kristian Reich, Kim Papp, Andrew Blauvelt et al. · The Lancet · 2017 · 556 citations

Medicine, Dermatology, Pharmacotherapy +10

Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials

Andrew Blauvelt, Kristian Reich, Kim Papp et al. · British Journal of Dermatology · 2018 · 75 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis

Anthony D Puopolo, Judith A. Boice, James Fidelholtz et al. · Osteoarthritis and Cartilage · 2007 · 59 citations

Medicine, Pharmacology, Pharmacotherapy +7

Analgesic Efficacy of Etoricoxib in Primary Dysmenorrhea: Results of a Randomized, Controlled Trial

Kerstin Malmström, Paul Kotey, N. Cichanowitz et al. · Gynecologic and Obstetric Investigation · 2003 · 48 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

Alexa B. Kimball, Kim Papp, Kristian Reich et al. · British Journal of Dermatology · 2019 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

1–5 of 6